Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, 
represents an important therapeutic advance in the treatment of pediatric 
high-risk neuroblastoma and is now considered part of standard of care in this 
patient population. To date, transverse myelitis as a result of dinutuximab 
therapy has not been reported in clinical trials or in the published literature. 
We describe three patients with clinical symptoms of transverse myelitis, 
confirmed via magnetic resonance imaging, shortly following initiation of 
dinutuximab. All patients were discontinued from dinutuximab treatment and 
received urgent treatment, with rapid improvement in symptoms and resultant 
functional recovery.